NO974727L - Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav - Google Patents

Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav

Info

Publication number
NO974727L
NO974727L NO974727A NO974727A NO974727L NO 974727 L NO974727 L NO 974727L NO 974727 A NO974727 A NO 974727A NO 974727 A NO974727 A NO 974727A NO 974727 L NO974727 L NO 974727L
Authority
NO
Norway
Prior art keywords
compositions
immunogenic
oligosaccharide
antigen
preparation
Prior art date
Application number
NO974727A
Other languages
English (en)
Other versions
NO974727D0 (no
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of NO974727D0 publication Critical patent/NO974727D0/no
Publication of NO974727L publication Critical patent/NO974727L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet immunogene oligosakkaridsammensetninger og fremgangsmåter for fremstilling av disse og anvendelser derav. Sammensetningene omfatter spesielt oligosakkarider kovalentlig koblet til bærerprotein, hvori det resulterende konjugatet er blitt vist å inneholde spesifikke immunogene epitoper og utløser en beskyttende immunogen respons. Det er også tilveiebrakt sammensetninger som omfatter et oligosakkarid av S. pneumoniae serotype 8 nyttig for stimulering av en immunrespons mot et antigen, fremgangsmåte for tilveiebringing av beskyttende immunisering mot et bakterielt patogen ved anvendelse av disse sammensetningene, fremgangsmåte for å forøke en immunogen respons mot et antigen ved administrering av disse S. pneumoniae serotype 8 oligosakkarid sammensetningene sammen med antigenet, og fremgangsmåte for fremstilling av immunstimulatoriske sammensetninger beskrevet ovenfor.
NO974727A 1995-06-07 1997-10-13 Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav NO974727L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
PCT/CA1996/000387 WO1996040225A1 (en) 1995-06-07 1996-06-06 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them

Publications (2)

Publication Number Publication Date
NO974727D0 NO974727D0 (no) 1997-10-13
NO974727L true NO974727L (no) 1997-12-08

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974727A NO974727L (no) 1995-06-07 1997-10-13 Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav

Country Status (10)

Country Link
EP (1) EP0831894A1 (no)
JP (1) JPH11506110A (no)
KR (1) KR19990007777A (no)
AU (1) AU725279B2 (no)
CZ (1) CZ327897A3 (no)
IL (1) IL121585A0 (no)
MX (1) MX9707944A (no)
NO (1) NO974727L (no)
NZ (1) NZ309713A (no)
WO (1) WO1996040225A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
RU2233172C2 (ru) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Иммуногенный коньюгат полисахарид h. influenzae - порин менингококка группы b (варианты), способ его получения, фармацевтическая композиция и способ индукции иммунного ответа у животного в отношении h.influenzae
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
WO2001098334A2 (en) * 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
SA114350400B1 (ar) * 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US12616744B2 (en) 2014-01-21 2026-05-05 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) * 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
KR102480429B1 (ko) * 2014-09-26 2022-12-21 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 스트렙토코커스 뉴모니에 혈청형 8에 대한 백신
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018328040B2 (en) * 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
JP7585203B2 (ja) * 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69027052T2 (de) * 1990-12-18 1996-09-26 Univ Washington Dialysat-produktionssystem mit pillen
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
JPH11506110A (ja) 1999-06-02
MX9707944A (es) 1998-06-30
EP0831894A1 (en) 1998-04-01
NZ309713A (en) 1999-11-29
IL121585A0 (en) 1998-02-08
KR19990007777A (ko) 1999-01-25
AU5994496A (en) 1996-12-30
AU725279B2 (en) 2000-10-12
CZ327897A3 (cs) 1998-02-18
NO974727D0 (no) 1997-10-13
WO1996040225A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
Chu et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
Schneerson et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates
EP0789587B2 (en) Combined meningitis vaccine
Devi et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity
Lagergard et al. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid
AU8483391A (en) Improved oligosaccharide conjugate vaccines
CA2188284C (en) Group a streptococcal polysaccharide immunogenic compositions and methods
AU3065489A (en) T-cell epitope as carriers molecule for conjugate vaccines
CA2142981A1 (en) Vaccines against group c neisseria meningitidis
JPH07506811A (ja) 二重担体の免疫原性構成体
WO1993017712A3 (en) Conjugates formed from heat shock proteins and oligo- or polysaccharides
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
Wetherell Jr et al. Antigens of Streptococcus mutans: characterization of a polysaccharide antigen from walls of strain GS-5
Pawlowski et al. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
Lieberman et al. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions
Takada et al. Serological characterization of Streptococcus mutans serotype polysaccharide g and its different molecular weight forms
Pier et al. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
RU2001107132A (ru) Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины, который получают с помощью n-акрилоилированного полисахарида
Jackson et al. Immune Responses to Lipoteichoic Acid: Comparison of Antibody Responses in Rabbits and Mice: Part II
Szu et al. Vaccines for prevention of enteric bacterial infections caused by Salmonellae
Kaijser et al. in Protection against Acute Pyelonephritis
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application